BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help
Search Results
Documents 1-2 out of 2 found
  Current Search:  maxipime: 2     
HTML
100%
Elan Focuses on New Tysabri Studies in 2010
Elan ELN reported full-year 2009 financial results that were in line with our estimates, as strong Tysabri growth and better cost control helped outweigh pressure from aging products and Elan's specialty pharma business.

As we discussed in our Biogen Idec...

Morningstar.ca:  Feb 10 2010 10:42PM
Matching: maxipime 		Find similar documents
HTML
100%
Financial Report: Elan 4Q
Elan 4Q 4Q Revenues: $300 million (+11%) 4Q Loss: $57.7 million (earnings were $169.5 million in 4Q08) FY Revenues: $1.1 billion (+11%) FY Loss: $176.2 million (loss of $71.0 million FY08) Comments: FY09 revenue from the Biopharmaceuticals business was up 20%...
Contract Pharma:  Feb 10 2010 5:05PM
Matching: maxipime 		Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.